3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 4
1
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Gastrointestinal Stromal Tumors
2
Progressive Gastrointestinal Stromal Tumor
1
Myeloproliferative Disorders
1
Mastocytosis, Systemic
1
Mastocytosis
1
Mast Cell Activation Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
nilotinib
1
fludarabine phosphate
1
fludarabine
1
bosutinib
1
asciminib
1
Phlebotomy
1
Imatinib Mesylate
1
Dasatinib
1
Busulfan
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Myeloproliferative Disorders
×
Imatinib Mesylate
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled